Literature DB >> 34876045

Clinical impact of multidrug-resistant bacteria in older hospitalized patients with community-acquired urinary tract infection.

Manuel Madrazo1, Ana Esparcia1, Ian López-Cruz1, Juan Alberola2,3, Laura Piles1, Alba Viana1, José María Eiros4, Arturo Artero1,5.   

Abstract

INTRODUCTION: Previous studies have described some risk factors for multidrug-resistant (MDR) bacteria in urinary tract infection (UTI). However, the clinical impact of MDR bacteria on older hospitalized patients with community-acquired UTI has not been broadly analyzed. We conducted a study in older adults with community-acquired UTI in order to identify risk factors for MDR bacteria and to know their clinical impact.
METHODS: Cohort prospective observational study of patients of 65 years or older, consecutively admitted to a university hospital, diagnosed with community-acquired UTI. We compared epidemiological and clinical variables and outcomes, from UTI due to MDR and non-MDR bacteria. Independent risk factors for MDR bacteria were analyzed using logistic regression.
RESULTS: 348 patients were included, 41.4% of them with UTI due to MDR bacteria. Median age was 81 years. Hospital mortality was 8.6%, with no difference between the MDR and non-MDR bacteria groups. Median length of stay was 5 [4-8] days, with a longer stay in the MDR group (6 [4-8] vs. 5 [4-7] days, p = 0.029). Inadequate empirical antimicrobial therapy (IEAT) was 23.3%, with statistically significant differences between groups (33.3% vs. 16.2%, p < 0.001). Healthcare-associated UTI variables, in particular previous antimicrobial therapy and residence in a nursing home, were found to be independent risk factors for MDR bacteria.
CONCLUSIONS: The clinical impact of MDR bacteria was moderate. MDR bacteria cases had higher IEAT and longer hospital stay, although mortality was not higher. Previous antimicrobial therapy and residence in a nursing home were independent risk factors for MDR bacteria.
© 2021. The Author(s).

Entities:  

Keywords:  Inadequate empirical antimicrobial therapy; Older adults; Outcomes; Risk factor

Mesh:

Substances:

Year:  2021        PMID: 34876045      PMCID: PMC8653523          DOI: 10.1186/s12879-021-06939-2

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


Introduction

Antimicrobial resistance has become a major worldwide healthcare problem and especially infections caused by multidrug-resistant (MDR) microorganisms as they have a huge clinical and economic burden [1, 2]. Although most of these infections are commonly associated with healthcare, MDR bacteria are also causing a growing number of community-acquired infections [3, 4]. Urinary tract infection (UTI) is among the most frequent causes of bacteremia and sepsis [5] and it is a very frequent cause of hospitalization due to infection in older adults [6]. Extended-spectrum beta-lactamases (ESBL) are enzymes produced by Escherichia coli and other bacteria that are common etiologies in UTI [7]. Simultaneous resistance to other antimicrobials is frequent since they are often encoded in the same plasmids that harbored the ESBL genes [8]. Therefore, MDR microorganisms are an increasing cause of UTI in both community-acquired and healthcare-associated infections [9-11] which could lead to a higher rate of treatment failure [12]. Previous studies have described some risk factors for MDR bacteria in UTI [13-15]. However, most of these studies are retrospective and include both nosocomial and community-acquired UTI. The clinical impact of MDR bacteria on older hospitalized patients with community-acquired UTI has not been broadly analyzed [16]. Therefore, we conducted a prospective study in older adults with community-acquired UTI admitted to hospital in order to identify risk factors for MDR bacteria and to know their clinical impact.

Material and methods

Cohort prospective observational study of patients of 65 years or older consecutively admitted to an internal medicine ward at a university hospital diagnosed with community acquired UTI, from January 2016 to December 2019. Cases with a negative urine culture or a clinical syndrome compatible with any other condition after reviewing the case were excluded, as well as nosocomial or UTI cases transferred from the Intensive Care Unit (ICU). Epidemiological and clinical variables were collected by the authors following a protocol. All the cases were reviewed by two independent researchers (MM and AE) before being included in the study. Multidrug-resistance (MDR) was defined according to an international expert proposal by Magiorakos et al. [17], as non-susceptibility to at least one agent in three or more antimicrobial categories (extended-spectrum penicillins, carbapenems, cephalosporins, aminoglycosides, and fluoroquinolones for gramnegative bacteria; and ampicillin, vancomycin, fluoroquinolones, fosfomycin and linezolid for grampositive bacteria). Extensively drug-resistance (XDR) was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories tested for a particular microorganism. SOFA and qSOFA scales were used according to their original definitions [18] and measured within 24 h of admission at the Emergency Department (ED). Community onset healthcare-associated UTI (HCA-UTI) was defined as a community onset UTI with any of the following criteria: (i) to have been admitted to an acute care hospital ≥ 48 h within 90 days previous to current hospital admission; (ii) to have received antimicrobial therapy within 90 days previous to admission; and (iii) residing in a nursing home [19]. IEAT was considered as the occurrence of infection that was not effectively treated at the time when the causative microorganism and its antimicrobial susceptibility were known. This included the absence of antimicrobial agents directed at a specific class of microorganisms and the administration of an antimicrobial agent to which the microorganism responsible for the infection was resistant [19]. Quantitative variables were compared using Student's t-test or analysis of variance (ANOVA) when the distribution was normal, or Mann–Whitney U-test when it was not normal. Qualitative variables were compared with chi square test and Fisher’s exact test. Multivariate analysis was performed using logistic regression, considering an α significance level of 0.05 for all tests. All tests were two sided. If any data was missing, a normal value was attributed for the calculation. The statistical package SPSS version 22 from IBM for Windows was used for the statistical analysis.

Results

Out of 1258 patients diagnosed with community acquired UTI admitted to hospital during the period of study, 348 patients were included (Fig. 1). MDR bacteria caused 41.4% of the cases, including 7.8% cases with XDR bacteria. Mean age was 81 years, and 51.4% were male. Diabetes mellitus (37.4%), chronic kidney disease (32.5%) and dementia (29.9%) were the most frequent comorbidities. 52.9% of the patients were septic and 16% had septic shock on admission. Other epidemiological and clinical characteristics and outcomes may be seen in Table 1.
Fig. 1

Flowchart of inclusion of hospitalized patients 65 years or older with community-acquired urinary tract infection

Table 1

Epidemiological and clinical characteristics and outcomes of community-acquired urinary tract infection in older patients according to multidrug-resistant or non-multidrug-resistant bacteria

Total casesn 348MDR bacterian 144Non-MDR bacterian 204p
Male sex, n (%)179 (51.4)82 (56.9)97 (47.5)0.102
Age (years), median [IQR]81 [75–87]80 [75–88]81 [75–87]0.719
Age ≥ 75 years, n (%)274 (78.7)111 (77.1)163 (79.9)0.595
McCabe ≥ 2, n (%)268 (77)113 (78.5)155 (75.9)0.607
Comorbidites
 Dementia, n (%)104 (29.9)52 (36.1)52 (25.5)0.043
 Diabetes mellitus, n (%)130 (37.4)56 (38.9)74 (36.3)0.653
 COPD, n (%)51 (14.7)20 (13.9)31 (15.2)0.761
 CKD, n (%)113 (32.5)44 (30.6)69 (33.8)0.562
 Cancer, n (%)77 (22.1)30 (20.8)47 (23)0.695
 Indwelling urinary catheter, n (%)81 (23.3)40 (27.8)41 (20.1)0.122
 HCA-UTI, n (%)214 (61.5)110 (76.4)104 (50.9) < 0.001
 Previous hospitalization, n (%)128 (36.8)67 (46.5)61 (29.9)0.002
 Previous antimicrobial therapy, n (%)182 (52.3)94 (65.3)88 (43.1) < 0.001
 Nursing home residence, n (%)28 (8)20 (13.9)8 (3.9)0.001
Clinical characteristics
 APACHE II, median [IQR]12 [9–17]13 [9–17]12 [9–17]0.981
 Fever, n (%)239 (68.7)98 (68.1)141 (69.1)0.907
 RR ≥ 22, n (%)71 (20.4)23 (15.9)48 (23.5)0.105
 Altered mental status, n (%)158 (45.4)76 (52.8)82 (40.2)0.021
 SBP < 100, n (%)62 (17.8)30 (20.8)32 (15.7)0.255
 qSOFA ≥ 2, n (%)90 (25.9)40 (27.8)50 (24.5)0.535
 Sepsis (SOFA ≥ 2), n (%)184 (52.9)78 (54.1)106 (51.9)0.744
 Septic shock-3, n (%)56 (16)25 (17.4)31 (15.2)0.657
 Albumin, median [IQR]3.1 [2.8–3.5]3.0 [2.7–3.5]3.2 [2.9–3.5]0.063
 Leukocytosis, median [IQR]13,200 [9400–18575]12,800 [9025–18425]13,500 [9750–18600]0.170
 Polymicrobial UTI, n (%)36 (10.3)21 (14.6)15 (7.4)0.033
 Bacteremia, positive/total blood cultures (%)84/209 (40.2)35/85 (41.2)49/124 (39.5)0.951
 IEAT, n (%)81 (23.3)48 (33.3)33 (16.2) < 0.001
Outcomes
 In-hospital mortality, n (%)30 (8.6)11 (7.6)19 (9.3)0.699
 30-day mortality, n (%)44 (12.6)20 (13.9)24 (11.8)0.624
 Length of hospital stay (days), median [IQR]5 [4–8]6 [4–8]5 [4–7]0.029

MDR, multidrug-resistant; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; HCA-UTI, healthcare associated-UTI; RR, respiratory rate; SBP, systolic blood pressure; IEAT, inadequate empiric antimicrobial therapy

Flowchart of inclusion of hospitalized patients 65 years or older with community-acquired urinary tract infection Epidemiological and clinical characteristics and outcomes of community-acquired urinary tract infection in older patients according to multidrug-resistant or non-multidrug-resistant bacteria MDR, multidrug-resistant; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; HCA-UTI, healthcare associated-UTI; RR, respiratory rate; SBP, systolic blood pressure; IEAT, inadequate empiric antimicrobial therapy Hospital mortality was 8.6% and 30-day mortality was 12.6%, with no difference between the MDR and non-MDR groups. Mean length of stay was 5 [4-8] days, with a longer stay in the MDR bacteria group. IEAT was 23.3%, with statistically significant differences between groups (33.3% vs. 16.2%, p < 0.001). MDR was associated with dementia, healthcare-associated UTI (including previous use of antimicrobials, previous admission at hospital and residing in a nursing home), and altered mental status at admission in the univariate analysis (Table 1). Healthcare-associated UTI variables, in particular previous antimicrobial therapy and residence in a nursing home, were found to be independent risk factors for MDR bacteria by multivariate analysis, but previous hospitalization was not (Table 2).
Table 2

Multivariate analysis by logistic regression of risk factors for multidrug-resistant bacteria producing urinary tract infection in older patients

Univariate analysis pOR (IC 95%)Multivariate analysis pOR (IC 95%)
Dementia0.0431.6 (1.1–1.7)0.255
Altered mental status0.0211.4 (1.1–1.8)0.197
Previous hospitalization0.0021.5 (1.2–1.9)0.433
Previous antimicrobial therapy < 0.0011.7 (1.3–2.5)0.0031.7 (0.6–2.9)
Residence in a nursing home0.0011.8 (1.4–2.4)0.0052.7 (0.8–4.6)
Multivariate analysis by logistic regression of risk factors for multidrug-resistant bacteria producing urinary tract infection in older patients Escherichia coli was the most frequent microorganism (56.4%), followed by Klebsiella pneumoniae (13.4%) and Enterococcus faecalis (8.5%), as shown in Table 3. The most frequent MDR bacteria were E. coli, K. pneumoniae and Enterobacter cloacae (60.5%, 12.6% and 6.7% of the total cases, respectively). There were no cases of panresistant bacteria. Multidrug-resistance in E. faecalis was low (6%), with just one case of resistance to Ampicillin and none to Vancomycin.
Table 3

Etiology of 348 cases of community-acquired urinary tract infection in older hospitalized patients according to multidrug-resistant and non-multidrug-resistant bacteria

Totaln 388MDR bacterian 147Non-MDR bacterian 241
Gramnegative bacteria, n (%)
 Escherichia coli219 (56.4)86 (39.26)133 (60.73)
 Klebsiella pneumoniae52 (13.4)20 (38.46)32 (61.54)
 Pseudomonas aeruginosa28 (7.2)7 (25)21 (75)
 Klebsiella oxytoca11 (2.8)3 (27.27)8 (72.72)
 Enterobacter cloacae10 (2.6)10 (100)0
 Proteus mirabilis9 (2.3)6 (66.67)3 (33.33)
 Other Enterobacteriaceae12 (3.1)8 (66.67)4 (33.33)
Grampositive bacteria, n (%)
 Enterococcus faecalis33 (8.5)2 (6.06)31 (93.94)
 Enterococcus faecium5 (1.3)1 (20)4 (80)
 Acinetobacter baumanii3 (0.8)3 (100)0
 Enterococcus gallinarum2 (0.5)1 (50)1 (50)
 Streptococcus agalactiae1 (0.3)01 (100)
Fungi, n (%)
 Candida spp.3 (0.8)03 (100)

MDR, multidrug-resistant

Etiology of 348 cases of community-acquired urinary tract infection in older hospitalized patients according to multidrug-resistant and non-multidrug-resistant bacteria MDR, multidrug-resistant Ampicillin showed the highest rate of resistance (75.6%), followed by ciprofloxacin (42.8%) and trimethoprim/sulfamethoxazole (40.5%). Resistance rates for Imipenem, Piperacillin/Tazobactam and Fosfomycin were low (4%, 6.4% and 15.6%, respectively), as well as resistance rate for Vancomycin among grampositive bacteria (4.3%).

Discussion

Our findings in this study indicate that the clinical impact of MDR bacteria in older patients with community-acquired UTI was moderate. There was no difference in mortality and, despite IEAT being twice the percentage in the MDR bacteria group, the length of hospital stay was just 1 day longer. In our study, MDR bacteria accounted for 41.4% of the cases of community-acquired UTI in hospitalized patients older than 65 years. This percentage is comparable to other results described in a similar setting (35.2% to 46.1%) [20-22], and higher than those of other studies on UTI outpatients (1.6% to 1.9%) [11, 23] or in the ED (6.7%) [24]. MDR cases were associated with IEAT (33.3% vs. 16.2%, p < 0.001) and a longer hospital stay (6 [4-8] vs. 5 [4-7] days, p = 0.029). Lee et al. [25], comparing MDR and non-MDR Enterobacteriaceae causing bacteraemic UTI, described similarly an effectiveness of empirical therapy of 43.5% vs. 93.9%, p < 0.001, and an increase in hospital stay (11.2 ± 6–62 vs. 9.27 ± 5.09 days, p < 0.001). In the same way, Tumbarello et al. [26] described an IEAT of 53.8% vs. 23.3% in a study with MDR and non-MDR P. aeruginosa UTI, as well as a longer hospital stay (48 vs. 22 days, p < 0.001). In our study, in-hospital mortality was 8.6% and 30-day mortality was 12.6%, both higher than that found in other studies (2.2% to 3.3% and 6 to 9.4%, respectively) [20, 27–29], in which the mean age of the patients was lower. Nevertheless, our findings were lower than that found by Karve et al. (15% and 18.6%) [22]. MDR bacteria were not associated with mortality, neither in-hospital mortality nor 30-day mortality, similarly to that found in other studies with younger adults patients [25, 26]. Studies on the effects of antibiotic resistance on fitness often document fitness costs of varying severity [30], and this could explain the no difference in mortality between resistant and non-resistant infections in our study, although there was a difference in appropriate and inappropriate antibiotic treatment. We would point out that in our study age and male sex were not associated with MDR bacteria, contrary to other studies on UTI, which included adult patients but not exclusively patients aged 65 or over [14, 16, 21]. It is a misconception that merely by being older, patients have more MDR infections. But this is not the case, as our findings suggest and in addition it can be seen in the works of Tumbarello et al. [26] and Faine et al. [24]. Comorbidities have been related to resistance in some studies [14, 25, 26], contrary to our results. In our study, only dementia and altered mental status on admission were significantly related to MDR in the univariate analysis, but not in the multivariate analysis, as in other studies with younger patients [16, 26]. Previous case history for healthcare related infection, in particular previous antimicrobial therapy or residence in a nursing home, was associated with MDR bacteria in our study. Previous antimicrobial therapy is one of the most important variables regarding multiresistance [14, 16, 21, 31] along with residing in a nursing home [14, 16, 21, 24, 31, 32]. Previous hospitalization has been related to resistance in some studies [14, 21, 31], but it was not significant in the multivariate analysis in our study, as well as in other works [16, 24, 32], The use of indwelling catheter has been traditionally related to the development of resistance [21, 26], but this was not the case in our results, as in other studies [16, 32]. ESBL-producing Enterobacteriaceae had a prevalence of 12.1% in our study, lower than the prevalence for ESBL-producing Enterobacteriaceae described in hospitalized patients in Europe (20%) [9] and North America (16.9%) [33], in studies with both community-acquired and nosocomial UTI. Our prevalence was similar to the 13.4% described by Smithson et al. [16] in older patients in the ED. The resistance to ciprofloxacin was 42.8%, similar to other studies (46.8% to 47.7%) [34, 35], which warrants not using ciprofloxacin as empirical antimicrobial therapy [34, 36]. Fosfomycin is an antimicrobial drug used mainly in primary care, where low resistance rate is described [11]. However, in recent years, it has also been recommended for patients with MDR bacteria such as ESBL producing Enterobacteriaceae [4, 37], especially in older patients [7]. The low resistance rate in our case (15.6%) corroborates its usefulness as empirical treatment. The main pathogens found in the urine culture, as expected, were E. coli, K. pneumoniae and E. faecalis. E. coli and K. pneumoniae were also the most frequent MDR bacteria (39.26% and 38.46% of the respective cases), similar to other studies describing gramnegative bacteria UTI [13] and Enterobacteriaceae-UTI [25]. There were only two cases of MDR E. faecalis, both in patients older than 85 years with healthcare associated infection, as described in other study [38], and none of them was resistant to vancomycin. The main strength of our study is that it was conceived from a clinical point of view, embracing all the UTI in the population of our interest, and avoiding possible confounders had the study stemmed from the results of the urine cultures. It is not centered on a group of resistant microorganism such as Enterobacteriaceae [27], Pseudomonas aeruginosa [26] or gramnegative bacteria [9]; and it does not select only one type of the clinical spectrum of UTI, such as bacteremic UTI [1, 25]. We think that this patient orientated approach and overall view may help the clinician to treat better older patients with community-acquired UTI. Other strengths are the prospective design, as well as its rigorous selection of cases, conducted in every case by two independent researchers. The main limitation of this work is that it was carried out in a single center, with the bias that it represents, especially regarding etiology and resistance rates. Population in our study corresponds to older patients admitted to an internal medicine department. Indeed, it is a strength because this population is not always well represented in other studies [16], but it is also a limitation, as our findings could differ in other populations with UTI, such as patients attended in the ED or admitted to the ICU and those with nosocomial UTI. Another limitation is that we did not collect the antecedent of UTI caused by a MDR bacteria, which has been proved to be an important risk factor for antimicrobial resistance [34, 39, 40]. All in all, we believe that our findings add knowledge on risk factors for community-acquired UTI caused by MDR-bacteria and on their clinical impact in older adults, which can lead to better management of UTI in this population.

Conclusion

In this prospective study in older patients with community-acquired UTI, the clinical impact of MDR bacteria was moderate. Cases caused by MDR bacteria had higher IEAT and longer hospital stay, although no higher mortality. MDR bacteria caused almost half of the cases of community-acquired UTI in our series, previous antimicrobial therapy and residence in a nursing home being independent risk factors.
  39 in total

Review 1.  Urinary Tract Infections in the Older Adult.

Authors:  Lindsay E Nicolle
Journal:  Clin Geriatr Med       Date:  2016-04-18       Impact factor: 3.076

2.  The impact of initial antibiotic treatment failure: Real-world insights in patients with complicated urinary tract infection.

Authors:  Sudeep Karve; Kellie Ryan; Pascale Peeters; Elisa Baelen; Sonia Rojas-Farreras; Danielle Potter; Jesús Rodríguez-Baño
Journal:  J Infect       Date:  2017-11-08       Impact factor: 6.072

3.  Inadequate empirical antimicrobial treatment in older people with bacteremic urinary tract infection who reside in nursing homes: A multicenter prospective observational study.

Authors:  Ana B Gómez Belda; Javier De la Fuente; Luis F Diez; Josep A Capdevila; Luis Inglada; Alexandra Arca; José M Romero; Cristina Serra-Centelles; Marta Domínguez-Gil; Arturo Artero
Journal:  Geriatr Gerontol Int       Date:  2019-10-01       Impact factor: 2.730

Review 4.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

5.  Management of Extended-Spectrum Beta-Lactamase Urinary Tract Infections: Diagnostic and Treatment Considerations for the Older Adult.

Authors:  Kalin M Clifford; Jennifer L Grelle; John C Tawwater; Meenakshi Ramanathan; Nakia Duncan
Journal:  Sr Care Pharm       Date:  2019-12-01

6.  A clinical decision rule identifies risk factors associated with antimicrobial-resistant urinary pathogens in the emergency department: a retrospective validation study.

Authors:  Brett A Faine; Kari K Harland; Blake Porter; Stephen Y Liang; Nicholas Mohr
Journal:  Ann Pharmacother       Date:  2015-03-20       Impact factor: 3.154

7.  Emergence of Extended-Spectrum β-Lactamase Urinary Tract Infections Among Hospitalized Emergency Department Patients in the United States.

Authors:  David A Talan; Sukhjit S Takhar; Anusha Krishnadasan; William R Mower; Daniel J Pallin; Manish Garg; Jon Femling; Richard E Rothman; Johanna C Moore; Alan E Jones; Frank Lovecchio; Jonathan Jui; Mark T Steele; Amy M Stubbs; William K Chiang; Gregory J Moran
Journal:  Ann Emerg Med       Date:  2020-10-31       Impact factor: 6.762

8.  Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals.

Authors:  Sameer S Kadri; Yi Ling Lai; Sarah Warner; Jeffrey R Strich; Ahmed Babiker; Emily E Ricotta; Cumhur Y Demirkale; John P Dekker; Tara N Palmore; Chanu Rhee; Michael Klompas; David C Hooper; John H Powers; Arjun Srinivasan; Robert L Danner; Jennifer Adjemian
Journal:  Lancet Infect Dis       Date:  2020-09-08       Impact factor: 25.071

Review 9.  Risk factors for aquiring multidrug-resistant organisms in urinary tract infections: A systematic literature review.

Authors:  Justin Tenney; Nicholas Hudson; Hazar Alnifaidy; Justin Ting Cheung Li; Kathy Harriet Fung
Journal:  Saudi Pharm J       Date:  2018-02-09       Impact factor: 4.330

10.  Clinical outcomes of hospitalised patients with catheter-associated urinary tract infection in countries with a high rate of multidrug-resistance: the COMBACTE-MAGNET RESCUING study.

Authors:  Aina Gomila; Jordi Carratalà; Noa Eliakim-Raz; Evelyn Shaw; Cristian Tebé; Martin Wolkewitz; Irith Wiegand; Sally Grier; Christiane Vank; Nienke Cuperus; Leonard Van den Heuvel; Cuong Vuong; Alasdair MacGowan; Leonard Leibovici; Ibironke Addy; Miquel Pujol
Journal:  Antimicrob Resist Infect Control       Date:  2019-12-03       Impact factor: 4.887

View more
  1 in total

1.  Infections in G6PD-Deficient Hospitalized Patients-Prevalence, Risk Factors, and Related Mortality.

Authors:  Diaa Alrahmany; Ahmed F Omar; Salima R S Al-Maqbali; Gehan Harb; Islam M Ghazi
Journal:  Antibiotics (Basel)       Date:  2022-07-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.